Janssen touches BACE with Shionogi for early-stage Alzheimer's candidates
This article was originally published in Scrip
Executive Summary
Janssen Pharmaceuticals has acquired rights to a series of oral inhibitors of the beta-site amyloid precursor protein-cleaving enzyme (BACE) in preclinical development for Alzheimer's disease at the Japanese firm Shionogi.